The first five-year cumulative revenue (2017–2021) global allergy diagnostics market is projected to reach US$ 5,417.6 Mn, as compared to a significantly higher cumulative revenue total of the latter five years of the forecast period (2022–2026). The inhaled allergen segment in the global allergy diagnostics market is estimated to account for the major revenue share of 48.3% in 2017.
Global Allergy Diagnostic Market: Segmental Snapshot
By product type: Assay kits segment is estimated to register a CAGR of over 13.0%, thereby accounting for highest revenue share among the type segments.
By allergen type: Inhaled allergen segment is estimated to account for highest revenue share among the allergen type segments, registering a CAGR of over 12.9% over the forecast period.
By end-user: laboratories segment is estimated to account for the highest revenue share among the allergen type segments, registering a CAGR of over 12.9% over the forecast period.
By region: The market in North America accounted for highest revenue share in the global allergy diagnostic market in 2016, and is expected to record highest CAGR of over 12.3% between 2016 and 2026.
Global Allergy Diagnostic Market: Competitive Analysis
The global allergy diagnostic market includes detailed competitive analysis on major companies such as Hitachi Chemical Diagnostics Inc., HOB Biotech Group Suzhou Co. Ltd., HUCOR Biomedical LLC, Quest Diagnostics Inc., Stallergenes Greer, BioMerieux SA, Omega Diagnostics Group PLC., Siemens AG, Lincoln Diagnostics.